The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL


  • Alisa M. Goldstein
  • May Chan
  • Mark Harland
  • Elizabeth M. Gillanders
  • Nicholas K. Hayward
  • Marie-Francoise Avril
  • Esther Azizi
  • Giovanna Bianchi-Scarra
  • D. Timothy Bishop
  • Brigitte Bressac-de Paillerets
  • William Bruno
  • Donato Calista
  • Lisa A. Cannon Albright
  • Florence Demenais
  • David E. Elder
  • Paola Ghiorzo
  • Nelleke A. Gruis
  • Johan Hansson
  • David Hogg
  • Elizabeth A. Holland
  • Peter A. Kanetsky
  • Richard F. Kefford
  • Maria Teresa Landi
  • Julie Lang
  • Sancy A. Leachman
  • Rona M. MacKie
  • Veronica Magnusson
  • Graham J. Mann
  • Kristin Niendorf
  • Julia Newton Bishop
  • Jane M. Palmer
  • Susana Puig
  • Joan A. Puig-Butille
  • Femke A. de Snoo
  • Mitchell Stark
  • Hensin Tsao
  • Margaret A. Tucker
  • Linda Whitaker
  • Emanuel Yakobson
  • Åke Borg
  • Håkan Olsson

Summary, in English

GenoMEL, comprising major familial melanoma research groups from North America, Europe, Asia, and Australia has created the largest familial melanoma sample yet available to characterize mutations in the high-risk melanoma susceptibility genes CDKN2A/alternate reading frames (ARF), which encodes p16 and p14ARF, and CDK4 and to evaluate their relationship with pancreatic cancer (PC), neural system tumors (NST), and uveal melanoma (UM). This study included 466 families (2,137 patients) with at least three melanoma patients from 17 GenoMEL centers. Overall, 41% (n = 190) of families had mutations; most involved p16 (n = 178). Mutations in CDK4 (n = 5) and ARF (n = 7) occurred at similar frequencies (2-3%). There were striking differences in mutations across geographic locales. The proportion of families with the most frequent founder mutation(s) of each locale differed significantly across the seven regions (P = 0.0009). Single founder CDKN2A mutations were predominant in Sweden (p.R112_L113insR, 92% of family's mutations) and the Netherlands (c.225_243del19, 90% of family's mutations). France, Spain, and Italy had the same most frequent mutation (p.G101W). Similarly, Australia and United Kingdom had the same most common mutations (p.M53I, cdVS2-105A > G, p.R24P, and p.L32P). As reported previously, there was a strong association between PC and CDKN2A mutations (P < 0.0001). This relationship differed by mutation. In contrast, there was little evidence for an association between CDKN2A mutations and NST (P = 0.52) or UM (P = 0.25). There was a marginally significant association between NST and ARF (P = 0.05). However, this particular evaluation had low power and requires confirmation. This GenoMEL study provides the most extensive characterization of mutations in high-risk melanoma susceptibility genes in families with three or more melanoma patients yet available.


  • Department of Clinical Sciences, Lund
  • Tumor microenvironment
  • Breastcancer-genetics

Publishing year







Cancer Research





Document type

Journal article


American Association for Cancer Research Inc.


  • Cancer and Oncology




  • ISSN: 1538-7445